Latest Phase II Data Bolster Cidara’s Antifungal

 
• By Sten Stovall

Cidara Therapeutics said new top-line results from the Phase II trial evaluating its lead asset as a first-line antifungal treatment in patients with candidemia and invasive candidiasis supported its ongoing Phase III ReSTORE program.

Candida
Rezafungin is a novel echinocandin antifungal being developed as a once-weekly therapy • Source: Shutterstock

More from Clinical Trials

More from R&D